ArticleAmerican journal of cancer research2026
Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) requires reliable biomarkers to guide the use of sorafenib or lenvatinib for personalized first-line treatment. This study investigated the association between salt-inducible kinase 2 (SIK2) expression and treatment outcomes in patients with advanced HCC receiving these tyrosine kinase inhibitors (TKIs). A retrospective cohort of 120 patients who received treatment from January 2022 to December 2024 was included. The expression of SIK2 was evaluated by immunohistochemistry, and the optimal H-score cut-off value of 6 was determined by ROC analysis. After 1:1 propensity score matching, 47 patients with high SIK2 expression and 47 patients with low SIK2 expression were compared. Patients with high SIK2 expression showed a significantly superior objective response rate (36.2% vs. 12.8%, P<0.001) and disease control rate (87.2% vs. 57.4%, P<0.001), as well as prolonged median overall survival (15.4 vs. 9.5 months; HR = 0.30, P<0.001) and progression-free survival (7.8 vs. 3.7 months; HR = 0.38, P<0.001). Multivariate analysis confirmed that low SIK2 expression was an independent predictor of poor OS (adjusted HR = 2.22, P<0.05) and PFS (adjusted HR = 1.96, P<0.05). Subgroup analysis showed that the prognostic value of SIK2 was consistent in the sorafenib and lenvatinib groups, and there was no significant interaction (P for interaction >0.05). Safety analysis showed that the incidence of adverse events between the two groups was comparable, while patients with low SIK2 expression had significant increases in liver enzymes and bilirubin after treatment (all P<0.05). In conclusion, low SIK2 expression independently predicts poor therapeutic response and survival in advanced HCC patients receiving first-line sorafenib or lenvatinib, with consistent predictive value across both TKIs. SIK2 represents a promising common predictive biomarker to guide personalized first-line targeted therapy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.